159 related articles for article (PubMed ID: 10560397)
41. Video-assisted management of malignant pleural effusion in breast carcinoma.
Gasparri R; Leo F; Veronesi G; De Pas T; Colleoni M; Maisonneuve P; Pelosi G; Galimberti V; Spaggiari L
Cancer; 2006 Jan; 106(2):271-6. PubMed ID: 16342163
[TBL] [Abstract][Full Text] [Related]
42. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study.
Chen WJ; Yuan SF; Yan QY; Xiong JP; Wang SM; Zheng WE; Zhang W; Sun HY; Chen H; Wu LL
Cancer Invest; 2012 Feb; 30(2):126-30. PubMed ID: 22148972
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion.
Balassoulis G; Sichletidis L; Spyratos D; Chloros D; Zarogoulidis K; Kontakiotis T; Bagalas V; Porpodis K; Manika K; Patakas D
Am J Clin Oncol; 2008 Aug; 31(4):384-9. PubMed ID: 18845999
[TBL] [Abstract][Full Text] [Related]
44. Uncertain benefit from surgery in patients with lung metastases from breast carcinoma.
Planchard D; Soria JC; Michiels S; Grunenwald D; Validire P; Caliandro R; Girard P; Le Chevalier T
Cancer; 2004 Jan; 100(1):28-35. PubMed ID: 14692021
[TBL] [Abstract][Full Text] [Related]
45. Management of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis.
Ohta Y; Shimizu Y; Matsumoto I; Watanabe G
J Exp Clin Cancer Res; 2006 Mar; 25(1):15-9. PubMed ID: 16761613
[TBL] [Abstract][Full Text] [Related]
46. [Two patients of recurrent breast cancer with carcinomatous pleurisy well controlled pleural effusion].
Hojo S; Maeura Y; Fukunaga H; Yoshioka S; Ota H; Endo W; Yamazaki K
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1795-7. PubMed ID: 16315944
[TBL] [Abstract][Full Text] [Related]
47. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
[TBL] [Abstract][Full Text] [Related]
48. Thoracoscopic collagen pleurodesis in the treatment of malignant pleural effusions.
Akopov AL; Egorov VI; Varlamov VV; Levashev YN; Artioukh DY
Eur J Cardiothorac Surg; 2005 Nov; 28(5):750-3. PubMed ID: 16198593
[TBL] [Abstract][Full Text] [Related]
49. Bedside talc pleurodesis for malignant pleural effusion: factors affecting success.
Aydogmus U; Ozdemir S; Cansever L; Sonmezoglu Y; Kocaturk CI; Bedirhan MA
Ann Surg Oncol; 2009 Mar; 16(3):745-50. PubMed ID: 19116753
[TBL] [Abstract][Full Text] [Related]
50. [Using a pleural implantable access system for the management of malignant pleural effusions. Experience of Institut Curie].
Daniel C; Kriegel I; Di Maria S; Patrubani G; Livartowski A; Estève M
Rev Pneumol Clin; 2008 Feb; 64(1):8-14. PubMed ID: 18603173
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Macaulay VM; O'Byrne KJ; Saunders MP; Braybrooke JP; Long L; Gleeson F; Mason CS; Harris AL; Brown P; Talbot DC
Clin Cancer Res; 1999 Mar; 5(3):513-20. PubMed ID: 10100701
[TBL] [Abstract][Full Text] [Related]
52. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
Sioris T; Sihvo E; Salo J; Räsänen J; Knuuttila A
Eur J Surg Oncol; 2009 May; 35(5):546-51. PubMed ID: 18644696
[TBL] [Abstract][Full Text] [Related]
53. Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion.
Chu H; Du F; Gong Z; Lian P; Wang Z; Li P; Hu B; Chi C; Chen J
Anticancer Res; 2017 Aug; 37(8):4587-4591. PubMed ID: 28739756
[TBL] [Abstract][Full Text] [Related]
54. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
55. Survival of patient with pleural involvement by breast carcinoma.
Poe RH; Qazi R; Israel RH; Wicks CM; Rubins JM
Am J Clin Oncol; 1983 Oct; 6(5):523-7. PubMed ID: 6613918
[TBL] [Abstract][Full Text] [Related]
56. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients.
Aoe K; Hiraki A; Yamazaki K; Nakamura Y; Murakami T; Maeda T; Nishimura M; Sugi K; Ueoka H
Int J Oncol; 2006 Jul; 29(1):65-72. PubMed ID: 16773186
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of visceral pleural invasion in resected non-small cell lung cancer diagnosed by using a jet stream of saline solution.
Maruyama R; Shoji F; Okamoto T; Miyamoto T; Miyake T; Nakamura T; Ikeda J; Asoh H; Yamaguchi M; Yoshino I; Ichinose Y
J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1587-92. PubMed ID: 15173711
[TBL] [Abstract][Full Text] [Related]
58. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
59. [Treatment of malignant pleural effusion by pleurodesis with talc].
Filippetti M; Crucitti G; Vanni B; Della Giulia M; Foggi P; Del Monte G
Chir Ital; 2000; 52(5):541-7. PubMed ID: 11190547
[TBL] [Abstract][Full Text] [Related]
60. [Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Kikumori T; Hayashi H; Shibata A; Sekiya M; Itoh T; Mase T; Oiwa M; Imai T; Funahashi H
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2091-4. PubMed ID: 10584578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
